Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK National Screening Committee.
Murphy
M F
MF
National Blood Service, Department of Haematology, Oxford Radcliffe Hospital and University of Oxford, UK. mike.murphy@nbs.nhs.uk
Williamson
L M
LM
D016824:Antigens, Human Platelet / Q000276:immunology; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D015994:Incidence; D007231:Infant, Newborn; D039661:Integrin beta3; D007518:Isoantibodies / Q000097:blood; D008403:Mass Screening / Q000592:standards*; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*; D012680:Sensitivity and Specificity; D013921:Thrombocytopenia / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D016896:Treatment Outcome; D006113:United Kingdom
D016824:Antigens, Human Platelet; C061248:ITGB3 protein, human; D016756:Immunoglobulins, Intravenous; D039661:Integrin beta3; D007518:Isoantibodies